Skip to main content
Midas Edge

VERTEX PHARMACEUTICALS INC / MA

For the period ended Mar 31, 2026. Filed May 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 5, 2026

VRTX$550.87+0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Shareholders' Equity

Three Months Ended
Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income (Loss) · Retained Earnings · Total Shareholders’ Equity
Shares · Amount
Balance at December 31, 2024256.9$2.6$6,672.4$127.8$9,606.8$16,409.6
Other comprehensive loss, net of tax———(59.7)—(59.7)
Net income————646.3646.3
Repurchases of common stock(0.9)—(416.9)——(416.9)
Common stock withheld for employee tax obligations(0.6)—(270.5)——(270.5)
Issuance of common stock under benefit plans1.6—18.5——18.5
Stock-based compensation expense——169.0——169.0
Balance at March 31, 2025257.0$2.6$6,172.5$68.1$10,253.1$16,496.3
Balance at December 31, 2025254.0$2.5$5,119.2$(15.9)$13,560.0$18,665.8
Other comprehensive income, net of tax———40.7—40.7
Net income————1,031.41,031.4
Repurchases of common stock(0.7)—(344.5)——(344.5)
Common stock withheld for employee tax obligations(0.5)—(228.5)——(228.5)
Issuance of common stock under benefit plans1.4—27.1——27.1
Stock-based compensation expense——169.9——169.9
Balance at March 31, 2026254.2$2.5$4,743.2$24.8$14,591.4$19,361.9
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.